The Relationship between Bevacizumab and Body Mass Index in Metastatic Colorectal Cancer
The Relationship between Bevacizumab and Body Mass Index in Metastatic Colorectal Cancer
ISSN: 2757-976X ;
E-ISSN: 2757-976X ;
- Year : 2024
- Vol : 4
- No : 1
- Page : 18-22
ÖZ
Aim: Bevacizumab is a target therapy drug inhibiting vascular endothelial growth factor (VEGF). High serum VEGF levels are related to increased visceral and abdominal fat mass. We aim to observe the relation of body mass index (BMI) with survival in metastatic colorectal cancer (mCRC) receiving bevacizumab with cytotoxic therapy.
Methods: The study included 90 metastatic colon cancer patients receiving bevacizumab-based systemic chemotherapy in first-line treatment. Study population was stratified into two according to the BMI. Group 1 was consisted of patients with a BMI lower than 25 kg/m 2 , Group 2 was consisted of patients with a BMI higher than 25 kg/m 2 . Overall survival (OS), progression free survival (PFS), clinic characteristics, laboratory parameters, and response rates were compared between the groups.
Results: The mPFS of group 1 and group 2 were 15.8 (95% Conf. Int: 10.1-21.5) and 15.6 (95% Conf. Int:10.1-21.5) months (p=0.4), respectively. The mOS was 22.6 (95% Conf. Int: 20.1-28.8) months for group 1 and 27.61 (95% Conf. Int: 21.81-29.92) months for group 2 (p=0.02). In multivariate analysis, BMI (Hazard Ratio: 0.89, 95% Conf. Int: 0.69-0.96, p=0.024) was determined to be a risk factor for OS.
Conclusion: Increased BMI was related with more prolonged survival in patients with mCRC receiving bevacizumab. Increased BMI was found to be an independent predictive marker for improved OS.
Methods: The study included 90 metastatic colon cancer patients receiving bevacizumab-based systemic chemotherapy in first-line treatment. Study population was stratified into two according to the BMI. Group 1 was consisted of patients with a BMI lower than 25 kg/m 2 , Group 2 was consisted of patients with a BMI higher than 25 kg/m 2 . Overall survival (OS), progression free survival (PFS), clinic characteristics, laboratory parameters, and response rates were compared between the groups.
Results: The mPFS of group 1 and group 2 were 15.8 (95% Conf. Int: 10.1-21.5) and 15.6 (95% Conf. Int:10.1-21.5) months (p=0.4), respectively. The mOS was 22.6 (95% Conf. Int: 20.1-28.8) months for group 1 and 27.61 (95% Conf. Int: 21.81-29.92) months for group 2 (p=0.02). In multivariate analysis, BMI (Hazard Ratio: 0.89, 95% Conf. Int: 0.69-0.96, p=0.024) was determined to be a risk factor for OS.
Conclusion: Increased BMI was related with more prolonged survival in patients with mCRC receiving bevacizumab. Increased BMI was found to be an independent predictive marker for improved OS.
Correspondence Address :
Necmettin Erbakan Üniversitesi Tıp Fakültesi TIBBİ ONKOLOJİ BD
Email : [email protected]
Cite this Article As : Koçak MZ, Araz M, Karakurt Eryilmaz M, Korkmaz M, Artac M. The Relationship between Bevacizumab and Body Mass Index in Metastatic Colorectal Cancer. Mev Med Sci. 2024; 4(1): 18-22
Description : Yazarların hiçbiri, bu makalede bahsedilen herhangi bir ürün, aygıt veya ilaç ile ilgili maddi çıkar ilişkisine sahip değildir. Araştırma, herhangi bir dış organizasyon tarafından desteklenmedi.Yazarlar çalışmanın birincil verilerine tam erişim izni vermek ve derginin talep ettiği takdirde verileri incelemesine izin vermeyi kabul etmektedirler. None of the authors, any product mentioned in this article, does not have a material interest in the device or drug. Research, not supported by any external organization. grant full access to the primary data and, if requested by the magazine they agree to allow the examination of data.
Email : [email protected]
Cite this Article As : Koçak MZ, Araz M, Karakurt Eryilmaz M, Korkmaz M, Artac M. The Relationship between Bevacizumab and Body Mass Index in Metastatic Colorectal Cancer. Mev Med Sci. 2024; 4(1): 18-22
Description : Yazarların hiçbiri, bu makalede bahsedilen herhangi bir ürün, aygıt veya ilaç ile ilgili maddi çıkar ilişkisine sahip değildir. Araştırma, herhangi bir dış organizasyon tarafından desteklenmedi.Yazarlar çalışmanın birincil verilerine tam erişim izni vermek ve derginin talep ettiği takdirde verileri incelemesine izin vermeyi kabul etmektedirler. None of the authors, any product mentioned in this article, does not have a material interest in the device or drug. Research, not supported by any external organization. grant full access to the primary data and, if requested by the magazine they agree to allow the examination of data.
The Relationship between Bevacizumab and Body Mass Index in Metastatic Colorectal Cancer, strArastirmaMakalesi,
2024, Vol. 4 (1)
2024, Vol. 4 (1)
Received :28.12.2023,
Accepted : 24.04.2024,
Published Online : 26.04.2024
Mevlana Medical Sciences Journal
ISSN: 2757-976X ;
E-ISSN: 2757-976X ;
-
strArastirmaMakalesi
-
View as PDF -
Keywords
bevacizumab, vegf, body mass index, survival, colorectal cancer